Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir.

ABSTRACT:

Aims

The aim was to evaluate the effect of boceprevir and telaprevir on dolutegravir pharmacokinetics (PK); the effect of dolutegravir on boceprevir and telaprevir PK was assessed through comparison with historical data for each hepatitis C virus (HCV) drug's prescribing information alone.

Methods

This was a single-centre, randomized, open-label, two-cohort, two-period, one-way study in healthy adult subjects. Dolutegravir 50 mg once daily was administered for 5 days in Period 1, and dolutegravir 50 mg once daily was coadministered with either boceprevir 800 mg every 8 h (Cohort 1) or telaprevir 750 mg every 8 h (Cohort 2) for 10 days in Period 2.

Results

No deaths or serious adverse events were reported during the study. Four subjects were withdrawn from the study be

SUBMITTER: Johnson M 

PROVIDER: S-EPMC4243878 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature